DoD Uniform Formulary Blanket Purchase Agreement/Additional Discount Program
BACKGROUND: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: August 2017. The following drug classes/subclass and agents will be reviewed:
Antiretrovirals Sub-Class: Other Agents
Aptivus, Crixivan, Edurant, Evotaz, Intelence, Invirase, Kaletra, Lexiva, Norvir, Prezcobix, Prezista, Rescriptor, Selzentry, Tybost, Viracept
Antiretrovirals Sub-Class: Combinations
Atripla, Complera, Genvoya, Odefsey, Stribild, Triumeq
Antiretrovirals Sub-Class: INSTIs
Isentress, Tivicay, Vitekta
Antiretrovirals Sub-Class: NRTIs
Descovy, Emtriva, Trizivir, Truvada, Viread, Ziagen
Corticosteroid Sub-Class: HAE
Berinert, Cinryze, Firazyr, Kalbitor, Ruconest
Insulins Sub-Class: Basal
Basaglar Kwikpen U-100, Lantus, Lantus Solostar, Levemir, Levemir Flexpen, Levemir Flextouch, Toujeo Solostar, Tresiba Flextouch U-100, Tresiba Flextouch U-200
RFQ: The RFQ, including UF BPA and UF ADP Appendices are attached herein. The historical utilization data including quantity dispensed and 30 day equivalents by month is also attached herein.
PRE-PROPOSAL CONFERENCE: See paragraphs 2.4 and 2.5 of the RFQ. Minutes will be posted herein.
CLINICAL PRESENTATIONS: Interested parties or potential offerors may provide clinical presentations. To schedule, call 1-210-536-6116. Clinical presentations must be made available on CD (not to be retained by POD San Antonio staff) at time of presentation. Flash drives are not authorized for use on DoD computers. We are also requesting a dossier. A few weeks prior to the meeting, we will send you a list of detailed questions.
POCs: See below and paragraph 2.3 of the RFQ.
For additional information, search for DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/.
(Section 743 document is for informational purposes only and is not part of the solicitation.)
Keith Boulware, Junior Contract Analyst, Phone 303-676-3911, Email keith.boulware.ctr@mail.mil - Keith Boulware, Email dha.detrick.cod-a.mbx.dha-uf-bpa-official@mail.mil
